Vertex Pharmaceuticals Operating Margin

<div class='circular--portrait' style='background:#754DEB;color: white;font-size:3em;padding-top: 35px;;'>VRT</div>
VRTX -- USA Stock  

 Earnings Call  This Week

Vertex Pharmaceuticals operating-margin fundamental analysis lookup allows you to check this and other indicators for Vertex Pharmaceuticals Incorpor or any other equity instrument. You can also select from a set of available indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations. Please continue to Equity Screeners to view more equity screening tools
Symbol
Refresh

Vertex Pharmaceuticals Operating Margin Analysis

Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
 2017 2018 2019 2020 (projected)
Receivables310.25 M414.87 M373.38 M402.86 M
Inventories111.83 M124.36 M111.92 M120.76 M
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKOSYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. It is also developing VX-659 and VX-445 that are Phase III clinical trials VX-121, a cystic fibrosis transmembrane conductance regulator corrector that is in Phase III clinical trial VX-150, an inhibitor that is in Phase IIb clinical trial for acute pain CTX001 that is in Phase III clinical trial for the treatment of beta-thalassemia and sickle cell diseases and a novel drug candidate, which is in Phase I clinical trial for the treatment for alpha-1 antitrypsin deficiency. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG Arbor Biotechnologies, Inc. Moderna Therapeutics, Inc. Genomics plc Merck KGaA Darmstadt, Germany X-Chem, Inc. Janssen Pharmaceuticals, Inc. Merck KGaA Kymera Therapeutics Ribometrix, Inc. and Molecular Templates, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
ReceivablesInventories
Operating Margin 
 = 
Operating Income 
Revenue 
X
100 
More About Operating Margin | All Equity Analysis
Vertex Pharmaceuticals Operating Margin  =
25.01 
ValuationFundamentalsBuy or Sell

Vertex Pharmaceuticals Operating Margin Over Time Pattern

 Vertex Pharmaceuticals Operating Margin 
    
  Timeline 

About Operating Margin

A good Operating Margin is required for a company to be able to pay for its fixed costs or pay out its debt which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against firm's competitors.
Compare to competition
Accumulated Other Comprehensive Income
Based on recorded statements Vertex Pharmaceuticals Incorpor has Operating Margin of 25.01%. This is 171.29% lower than that of the Healthcare sector, and 122.32% lower than that of Biotechnology industry, The Operating Margin for all stocks is 553.9% lower than the firm.

Did you try this?

Run Financial Widgets Now

   

Financial Widgets

Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
All  Next Launch Module

Vertex Pharmaceuticals current financial ratios